Cover Image

Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)

Saved in:

Bibliographic Details
Main Authors:	Peng-Hui Wang (Author), Chia-Hao Liu (Author), Szu-Ting Yang (Author)
Format:	Book
Published:	Elsevier, 2024-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (II): Anti-HER2/neu
by: Peng-Hui Wang, et al.
Published: (2024)

Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer - The ABCs of ADCs (Antibody drug Conjugates)
by: J. Martin, et al.
Published: (2023)

New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development
by: Kira-Lee Koster, et al.
Published: (2022)

Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
by: Yan Liang, et al.
Published: (2024)

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development
by: Manar Hammood, et al.
Published: (2021)

Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment
by: Xiaolan Xu, et al.
Published: (2024)

Limitations of employing antibody drug conjugates (ADCs) for targeting HIV infected cells as a strategy for hiv cure
by: J. Strizki, et al.
Published: (2015)

Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database
by: PingPing Long, et al.
Published: (2024)

A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
by: Linlin Tang, et al.
Published: (2024)

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
by: Marta Nerone, et al.
Published: (2022)

The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin
by: Maurizio Cianfriglia
Published: (2013)

Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology
by: Debra L. Richardson
Published: (2023)

The role of sialylation in gynecologic cancers
by: Szu-Ting Yang, et al.
Published: (2023)

Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives
by: Cristina Martín-Sabroso, et al.
Published: (2021)

Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
by: McNamara B, et al.
Published: (2023)

The Chemistry Behind ADCs
by: Vesela Kostova, et al.
Published: (2021)

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer
by: An-Jin Wang, et al.
Published: (2022)

Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024)

Antibody-drug conjugates for cancer therapy
by: Anna Grzywa
Published: (2021)

Antibody-Drug Conjugates: The Last Decade
by: Nicolas Joubert, et al.
Published: (2020)

Antibody-Drug Conjugate to Treat Meningiomas
by: Kai Chen, et al.
Published: (2021)

ADC: a deadly killer of platinum resistant ovarian cancer
by: Xu Cheng, et al.
Published: (2024)

Antibody-drug conjugates: Recent advances in payloads
by: Zhijia Wang, et al.
Published: (2023)

Exploration of the antibody-drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023)

Therapeutic index improvement of antibody-drug conjugates
by: Hans-Peter Gerber, et al.
Published: (2023)

Antibody-drug conjugates combinations in cancer treatment
by: Giulia Pretelli, et al.
Published: (2024)

Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches
by: Ahmad Fawzi Hussain, et al.
Published: (2021)

Antibody-drug conjugates: beyond current approvals and potential future strategies
by: Siddharth Menon, et al.
Published: (2022)

Interrogating heterogeneity of cysteine-engineered antibody-drug conjugates and antibody-oligonucleotide conjugates by capillary zone electrophoresis-mass spectrometry
by: Tian Xu, et al.
Published: (2023)

Breakthroughs in women's health for treating vasomotor symptoms
by: Peng-Hui Wang, et al.
Published: (2024)

Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
by: Puey-Ling Chia, et al.
Published: (2020)

Targeting cancer with antibody-drug conjugates: Promises and challenges
by: Alexis Q. Dean, et al.
Published: (2021)

Antibody-drug conjugates: Recent advances in linker chemistry
by: Zheng Su, et al.
Published: (2021)

Recent advances of antibody drug conjugates for clinical applications
by: Pengxuan Zhao, et al.
Published: (2020)

The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
by: Seungmin Han, et al.
Published: (2022)

Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
by: Rotimi Sheyi, et al.
Published: (2022)

Previous radiation patients may not be a good candidate to consider the adding bevacizumab for rescue therapy
by: Yiu-Tai Li, et al.
Published: (2023)

The Analysis of Key Factors Related to ADCs Structural Design
by: Haichao Tang, et al.
Published: (2019)

Analytical Methods for the Detection and Quantification of ADCs in Biological Matrices
by: Héloïse Cahuzac, et al.
Published: (2020)

How Far Have We Developed Antibody-Drug Conjugate for the Treatment of Cancer?
by: Yu Jun Lim, et al.
Published: (2023)